scholarly journals T2 breast cancer presenting with diffuse liver metastases and hepatic failure following fertility treatment. Cautionary report

2016 ◽  
Vol 27 ◽  
pp. 152-154 ◽  
Author(s):  
Emmanuel A. Sule
Keyword(s):  
Breast Cancer ◽  
Liver Metastases ◽  
Hepatic Failure ◽  
Fertility Treatment

End-Stage Acute Hepatic Failure as Clinical Presentation of Liver Metastases from Breast Cancer

1998 ◽  
Vol 84 (5) ◽  
pp. 616-617 ◽  
Author(s):  
Yago Nieto ◽  
José Luis Alonso ◽  
Francisco Ayala ◽  
Luis Ortega ◽  
Antonio Casado ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Liver Disease ◽  
Liver Metastases ◽  
Breast Neoplasm ◽  
Hepatic Failure ◽  
Unusual Case ◽  
Clinical Presentation ◽  
Acute Hepatic Failure ◽  
History Of ◽  
End Stage

A most unusual case of fatal acute hepatic failure as clinical presentation of liver metastases from breast cancer is described. The patient had a four-year history of indolent breast neoplasm and no previously known liver disease.

scholarly journals Radiographically occult intrasinusoidal liver metastases leading to hepatic failure in a case of breast cancer

2016 ◽  
pp. bcr2015214120 ◽  
Author(s):  
Seema Gulia ◽  
Sachin Khurana ◽  
Tanuja Shet ◽  
Sudeep Gupta
Keyword(s):  
Breast Cancer ◽  
Liver Metastases ◽  
Hepatic Failure

scholarly journals Eribulin, Child-Pugh score, and liver-function tests: lessons from pivotal breast cancer studies 301 and 305

2021 ◽  
Vol 23 (1) ◽  
Author(s):  
Iain R. Macpherson ◽  
Yaohua He ◽  
Carlo Palmieri
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Liver Function ◽  
Liver Metastases ◽  
Aspartate Aminotransferase ◽  
Alanine Aminotransferase ◽  
Hepatic Impairment ◽  
Metastatic Breast ◽  
Dose Modifications ◽  
Group D

Abstract Background The recommended starting dose of eribulin in patients with hepatic impairment is based on the Child-Pugh score, largely informed by a pharmacokinetic study of 18 patients. In the pivotal studies of eribulin in metastatic breast cancer (Study 301 and Study 305 [EMBRACE]), entry criteria and dose modifications were based on liver-function test (LFT) results rather than Child-Pugh score. In populations such as patients with metastatic breast cancer, in which metastatic infiltration is the predominant cause of hepatic impairment, using Child-Pugh score may be problematic; in clinical practice, it has been more common for oncologists to make dosing decisions based on LFTs. To address this, the effects of abnormal baseline LFT results on eribulin efficacy and safety were investigated. Methods In this pooled post hoc analysis, 1062 patients who were randomized to receive eribulin in Studies 301 and 305 were divided into 4 groups: (A) no elevated LFT results (no liver impairment); (B) increased levels of aspartate aminotransferase and/or alanine aminotransferase; (C) decreased albumin and/or increased levels of aspartate aminotransferase and/or alanine aminotransferase but not increased bilirubin; and (D) increased bilirubin. Patients were subcategorized by presence of liver metastasis. Drug exposure, dose intensity, and treatment-emergent adverse events (TEAEs) were analyzed. Results Eribulin mesylate mean dosage was 0.82 (group A)–0.65 mg/m2/week (group D). Group D had shorter treatment, more dose reductions/delays, more TEAEs leading to dose modifications, and numerically lower objective response rates and clinical benefit rates versus groups A–C. TEAE rates leading to dose modification were similar between group D (45.5%) and groups A–C (range, 43.5–54.9%) in the absence of liver metastases, but higher in group D (91.3%) compared with groups A–C (range, 41.7–54.3%) if liver metastases were present. Conclusions Mild elevations in bilirubin levels were associated with increased toxicity and a greater requirement for dose modifications. Based both on these study data and existing recommendations, we propose a novel scheme to guide initial dose selection in patients with metastatic breast cancer and hepatic impairment that is based on LFTs rather than Child-Pugh score.

scholarly journals Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Stephen Johnston ◽  
Joyce O’Shaughnessy ◽  
Miguel Martin ◽  
Jens Huober ◽  
Masakazu Toi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Progesterone Receptor ◽  
Liver Metastases ◽  
Advanced Breast Cancer ◽  
Performance Status ◽  
Objective Response ◽  
Advanced Breast ◽  
Treatment Benefit ◽  
Significant Treatment

AbstractIn MONARCH 3, continuous dosing of abemaciclib with an aromatase inhibitor (AI) conferred significant clinical benefit to postmenopausal women with HR+, HER2− advanced breast cancer. We report data for clinically prognostic subgroups: liver metastases, progesterone receptor status, tumor grade, bone-only disease, ECOG performance status, and treatment-free interval (TFI) from an additional 12-month follow-up (after final progression-free survival [PFS] readout). In the intent-to-treat population, after median follow-up of approximately 39 months, the updated PFS was 28.2 versus 14.8 months (hazard ratio [HR], 0.525; 95% confidence interval, 0.415–0.665) in abemaciclib versus placebo arms, respectively. Time to chemotherapy (HR, 0.513), time to second disease progression (HR, 0.637), and duration of response (HR, 0.466) were also statistically significantly prolonged with the addition of abemaciclib to AI. Treatment benefit was observed across all subgroups, as evidenced by objective response rate change from the addition of abemaciclib to AI, with the largest effects observed in patients with liver metastases, progesterone receptor-negative tumors, high-grade tumors, or TFI < 36 months. Extended follow-up in the MONARCH 3 trial further confirmed that the addition of abemaciclib to AI conferred significant treatment benefit to all subgroups, including those with poorer prognosis.

Hepatic arterial therapy with oxaliplatin and systemic capecitabine for patients with liver metastases from breast cancer

The Breast ◽  
2019 ◽  
Vol 43 ◽  
pp. 113-119 ◽  
Author(s):  
S.C. Lindgaard ◽  
C.M. Brinch ◽  
B.K. Jensen ◽  
H.H. Nørgaard ◽  
K.L. Hermann ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Liver Metastases

scholarly journals Efficacy of Combined Regional Inductive Moderate Hyperthermia and Chemotherapy in Patients With Multiple Liver Metastases From Breast Cancer

2018 ◽  
Vol 17 ◽  
pp. 153303381880600 ◽  
Author(s):  
Mykhailo Yu Klimanov ◽  
Liubov A. Syvak ◽  
Valerii E. Orel ◽  
G. V. Lavryk ◽  
Tetiana Ye Tarasenko ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Liver Metastases ◽  
Multiple Liver Metastases

scholarly journals A Case of Multiple Liver Metastases after Surgery in Elderly HER2-Positive Breast Cancer in Which Anastrozole + Trastuzumab Was Ineffective but T-DM1 Was Effective

2021 ◽  
pp. 1632-1637
Author(s):  
Tomohiro Shidahara ◽  
Shozo Ohsumi ◽  
Yuichiro Miyoshi ◽  
Mina Takahashi ◽  
Seiki Takashima ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Liver Metastases ◽  
Growth Factor Receptor ◽  
Complete Response ◽  
Lymph Node Biopsy ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Pathological Result ◽  
Multiple Liver Metastases ◽  
Positive Breast Cancer

Chemotherapy is often difficult to treat human epidermal growth factor receptor 2 (HER2)-positive metastatic recurrent breast cancer in the elderly, and no standard treatment has been established at this point. We experienced a case in which trastuzumab (Tmab) + anastrozole (ANA) was ineffective (progressive disease; PD) in elderly HER2-positive breast cancer with postoperative multiple liver metastases, but T-DM1 was significantly effective (complete response; CR), and treatment could be continued safely. An 82-year-old woman was referred to our department with a right breast mass. A close examination revealed right breast cancer cT1bN0M0 cStage I, and total mastectomy and sentinel lymph node biopsy were performed. The postoperative pathological result was pT1bN0M0 pStage I (luminal HER2 type). The patient was elderly and had no adjuvant treatment after the operation. Approximately 2 years after the operation, multiple liver metastases were observed, and treatment with ANA and Tmab was started. Four months later, MRI showed that the number of multiple liver metastases increased. The patient was diagnosed with PD, and the anti-HER2 drug was changed from trastuzumab to trastuzumab emtansine (T-DM1). The dose was reduced due to vomiting (grade 3). Two months later, MRI showed that the multiple liver metastases shrank and became obscure after 5 months. After that, T-DM1 was continued, and the disease did not worsen. In elderly people with difficulty in administering chemotherapy, T-DM1 may have a safe and sufficient therapeutic effect by adjusting the dose and managing side effects appropriately.

Sign in / Sign up

Export Citation Format

Share Document